Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BARF RCT: Fosaprepitant vs Metoclopramide for Nausea and Vomiting
NCT06740812Phase 4Not yet recruiting
- Sponsor
- Montefiore Medical Center
- Start
- Dec 2026
- Primary completion
- Sep 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of fosaprepitant in nausea ((none)) and Vomiting (2 arms), sponsored by Montefiore Medical Center. Primary endpoints: Sustained Nausea and Vomiting Relief at 2 hours and Development of New Symptom at 2 hours. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
fosaprepitant
03
Conditions
nausea ((none))Vomiting
Beyond the preview
Go deeper on NCT06740812.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06740812.